News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

IsoTis OrthoBiologicsAppoints Jim Poser As VP R&D And CTO



7/6/2006 3:44:42 PM

LAUSANNE, Switzerland and IRVINE, California, July 6 /PRNewswire-FirstCall/ -- IsoTis S.A., the orthobiologics company , today announced it has appointed James William (Jim) Poser, Ph.D., as Vice President Research & Development and Chief Technology Officer. Jim Poser, who is also a member of the IsoTis Scientific Advisory Board, has served as a close advisor to IsoTis since 2005.

Pieter Wolters, President and CEO of IsoTis OrthoBiologics said: "We are very pleased to welcome Jim Poser to head our R&D effort. Jim brings a wealth of product development and executive management experience in the orthobiologics field. With his impressive industry experience that spans more than 25 years we are confident that Jim will enable us to further strengthen our product portfolio and that he will play a key role in fulfilling our ambition to be a leader in the fast growing biology segment of the orthopaedic market."

From 2001 to 2004, Jim Poser was at Stryker Orthopaedics, Inc. as Vice President & General Manager Bone Substitutes. From 1994 to 2001, Mr. Poser was at Orquest, Inc., which was acquired by DuPuy, Inc. At Orquest, a company focused on developing biologically-based implants for orthopaedics and spine surgery, he held the VP of R&D position before being promoted to Senior Executive and Chief Scientific Officer in 1999. Prior to that Mr. Poser held different senior clinical and R&D positions in industry, among others at Osteotech, Inc. and Procter & Gamble.

IsoTis will publish its Q2 2006 results on August 3 before markets open, and conduct a conference call to discuss these results at 1:30 PM CET (7:30 AM ET).

IsoTis OrthoBiologics has a product portfolio with several innovative and proprietary natural and synthetic bone graft substitutes on the market and others in development, an established North American independent distribution network, and an expanding international presence. The company's main commercial operations are based out of Irvine, CA; its international sales headquarters is based in Lausanne, Switzerland.

IsoTis OrthoBiologics

CONTACT: For information contact: Hans Herklots, Director IR, Tel:+41(0)21-620-6011, E-mail: hans.herklots@isotis.com, Rob Morocco, CFO,+1-949-855-7155, robert.morocco@isotis.com


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES